Pfizer's lower-than-expected EPS guidance for FY24 suggests that the Seagen acquisition may have a significant impact on its financials, likely leading to short-term negative sentiment among investors. The substantial difference between the guidance and consensus indicates that the market may not have fully priced in the costs and implications of the acquisition, which could result in a downward pressure on Pfizer's stock price in the short term.